CareDx Responds To Natera's Filing Of A Motion For An Injunction Related To Patent 11,111,544; CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New Allosure Process That It Believes Does Not Infringe On The '544 Patent.
CareDx Responds To Natera's Filing Of A Motion For An Injunction Related To Patent 11,111,544; CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New Allosure Process That It Believes Does Not Infringe On The '544 Patent.
CareDx Reiterates Position that it Does Not Infringe Natera's '544 Patent
CaredX 重申其不侵犯 Natera '544 专利的立场
Injunction Motion has No Impact on CareDx's Business or Patient and Clinician Access to AlloSure or AlloMap
禁令动议对CaredX的业务或患者和临床医生获得AlloSure或AlloMap的机会没有影响
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.'s filing of a motion for an injunction related to patent 11,111,544 (the '544 patent).
CareDx, Inc.（纳斯达克股票代码：CDNA）——移植公司专注于为移植患者和护理人员发现、开发和商业化具有临床差异化的高价值医疗保健解决方案——今天对Natera, Inc.做出了回应。正在提交与专利11,111,544号（'544号专利）相关的禁令动议。
The motion seeks to stop CareDx from using a prior AlloSure process that Natera alleged infringed the '544 patent. That process is no longer in effect. As CareDx informed Natera and the Court, since August 2023, CareDx has utilized a new AlloSure process that it believes does not infringe on the '544 patent.
该议案旨在阻止CaredX使用先前的AlloSure程序，纳泰拉指控该程序侵犯了'544年专利。该程序已不再有效。正如CaredX告知纳特拉和法院的那样，自2023年8月以来，CaredX一直在使用新的AlloSure程序，它认为该程序没有侵犯'544年专利。
The underlying validity of the '544 patent also remains subject to judicial review.
'544专利的基本有效性也仍有待司法审查。
"We believe the motion against a process that is no longer in effect is irrelevant, and the District Court is still considering the fundamental question of the validity of the '544 patent," said John W. Hanna, CareDx President and CEO. "We greatly appreciate the continued support of the transplant community as we seek to resolve these matters, allowing us to return our full attention to serving patients and developing clinical innovations that improve transplant care."
CaredX总裁兼首席执行官约翰·汉纳表示：“我们认为，反对已失效程序的动议无关紧要，地方法院仍在考虑'544年专利有效性的根本问题。”“我们非常感谢移植界在我们寻求解决这些问题时给予的持续支持，这使我们能够将全部精力重新放在为患者提供服务和开发改善移植护理的临床创新上。”
Natera has previously claimed infringement on three patents:
Natera此前曾声称侵权了三项专利：
- Prior to trial, the District Court dismissed patent 10,597,724 (the '724 patent) as invalid as patent ineligible.
- At trial, CareDx was found not to have infringed on patent 10,655,180 (the '180 patent).
- The '544 patent is the subject of post-trial motion practice in which, among other things, CareDx is seeking to invalidate that patent on the same grounds as the '724 patent.
- 在审判之前，地区法院驳回了10,597,724号专利（'724专利）无效，因为该专利不符合资格。
- 在审判中，CaredX被认定没有侵犯10,655,180号专利（'180年专利）。
- '544专利是审后动议实践的主题，除其他外，CaredX正寻求以与'724专利相同的理由宣布该专利无效。
Natera's motion does not impact CareDx's business or ability to continue providing transplant patients with AlloSure or AlloMap.
纳泰拉的动议不会影响CaredX的业务或继续为移植患者提供AlloSure或AlloMap的能力。